M
Mark Blick
Researcher at University of Texas MD Anderson Cancer Center
Publications - 64
Citations - 3174
Mark Blick is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic myelogenous leukemia & breakpoint cluster region. The author has an hindex of 27, co-authored 64 publications receiving 3147 citations. Previous affiliations of Mark Blick include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Journal Article
Phase I Study of Recombinant Tumor Necrosis Factor in Cancer Patients
TL;DR: RTNF was well tolerated clinically in this dose range, and there was evidence of antitumor effect, and the clearance of rTNF in the serum was described by a monoexponential equation with a half-life calculated to be 14-18 min.
Journal ArticleDOI
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
Razelle Kurzrock,Mordechai Shtalrid,Paolo Romero,William S. Kloetzer,Moshe Talpas,Jose M. Trujillo,Mark Blick,Miloslav Beran,Jordan U. Gutterman +8 more
TL;DR: It is reported that the Ph translocation in acute lymphoblasticleukaemia can result in production of a novel aberrant c-abl protein that is distinct from the bcr-ablprotein found in Ph-positive chronic myelogenous leukaemia.
Journal ArticleDOI
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
TL;DR: This study forms the framework for phase II trials of IV administered rTNF-alpha, with the maximum tolerated dose (MTD) was 200 micrograms/m2 with dose limiting toxicity being constitutional symptoms and hypotension.
Journal ArticleDOI
Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II
Leonard A. Zwelling,Michael Hinds,Diana Chan,Janice Mayes,Kiem Lan Sie,Elizabeth Parker,L. Silberman,A. Radcliffe,Miloslav Beran,Mark Blick +9 more
TL;DR: It is shown that an m-AMSA-resistant form of topoisomerase II contributes to the resistance of HL-60/AMSA to m- AMSA and to other topoisomersase II-reactive DNA intercalating agents.
Journal ArticleDOI
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis
Aysegul A. Sahin,Jae Y. Ro,Adel K. El-Naggar,Nelson G. Ordóñez,Alberto G. Ayala,Jungsil Ro,Gabriel N. Hortobagyi,Mark Blick,Herbert A. Fritsche,Terry L. Smith +9 more
TL;DR: The results suggest that Ki‐67 immunostaining correlates well with nuclear grade and clinical outcome in node‐negative breast carcinoma, and both 5‐year disease‐free and overall survivals were strongly associated with percentage of cells stained with Ki‐ 67 antibody.